5 assets in Cushing Syndrome

Therapeutic assets addressing Cushing Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
(R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone Cushing Syndrome	Corcept Therapeutics	P3	BBB (72)
Mifepristone Cushing Syndrome	Corcept Therapeutics	P4	B (62)
Clofutriben Cushing Syndrome	Sparrow Pharmaceuticals	P2	CCC (53)
Semaglutide Cushing Syndrome	University of Texas Southwestern Medical Center	N/A	D (30)